Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Rhea-AI Summary

Voyager Therapeutics (VYGR), a biotech company focused on genetic treatments for neurological diseases, announced its participation in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference. CEO Alfred W. Sandrock, Jr., M.D., Ph.D., along with other management team members, will be featured in a pre-recorded fireside chat. The presentation will be available as an on-demand webcast starting June 17, 2025, at 7:00 a.m. ET through the Investors section of Voyager's website. The webcast recording will remain accessible for a minimum of 30 days after the event.

LEXINGTON, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager, and additional members of management will participate in a pre-recorded fireside chat at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference.

An on-demand webcast of the pre-recorded fireside chat will be available and may be accessed from the Investors section of Voyager’s website at ir.voyagertherapeutics.com starting at 7:00 a.m. ET on June 17, 2025. The on-demand webcast will be archived on the Company’s website for at least 30 days.

About Voyager Therapeutics
Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes programs for Alzheimer’s disease, Friedreich’s ataxia, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACER™ AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; and Neurocrine Biosciences, Inc. For more information, visit http://www.voyagertherapeutics.com.

Voyager Therapeutics^® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc. 

Contacts
Trista Morrison, NACD.DC, tmorrison@vygr.com
Investors: Sarah McCabe, smccabe@jpa.com
Media: Brooke Shenkin, brooke@scientpr.com

FAQ

When is Voyager Therapeutics (VYGR) presenting at the H.C. Wainwright Neuro Conference?

The pre-recorded fireside chat will be available as an on-demand webcast starting June 17, 2025, at 7:00 a.m. ET.

Who will represent Voyager Therapeutics at the H.C. Wainwright conference?

CEO Alfred W. Sandrock, Jr., M.D., Ph.D., and additional members of management will participate in the presentation.

How can investors access Voyager's presentation at the H.C. Wainwright conference?

Investors can access the webcast through Voyager's website at ir.voyagertherapeutics.com in the Investors section.

How long will Voyager's conference presentation be available for viewing?

The on-demand webcast will be archived on the Company's website for at least 30 days.